Since both FLT3-TKD and FLT3-ITD mutations are common in ETP-ALL and the prevalence of FLT3 mutations can be up to 35%, the use of an FLT3 inhibitor also provides a novel treatment approach. The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.